Back

The dilemma of recurrent hyperkalaemia and use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: a European multi-national targeted chart review

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Professor Patrick Rossignol

The Princess Grace Hospital Centre, Monaco (Monaco)

61 More presentations in this session

Presentation thumbnail
Real-world patterns of loop diuretics dose adjustment and association with outcomes in outpatients with chronic heart failure: observations from the ESC Heart Failure Long-Term Registry
Doctor C. Kapelios (Athens, GR)
Abstract Slides
Presentation thumbnail
Acute kidney failure and hyperkalaemia in patients with chronic hearth failure treated with aldosterone antagonists- a risk-benefit network meta-analysis
Presentation thumbnail
Intermittent administration of levosimendan ambulatory in patients with advanced chronic heart failure: experience in our center.
Presentation thumbnail
Sildenafil for chronic heart failure : a meta-analysis
Mrs C. Ariano (Naples, IT)
Abstract
Presentation thumbnail
Gender differences in heart failure treatment in the Netherlands: a subgroup analysis of the CHECK-HF registry
Mr J. Veenis (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources